ADDvise Group B — Management Reports 2023

Feb 23, 2023

ADDvise

PRESS RELEASE

Stockholm February 23, 2023

ADDvise presents financial targets for 2023

The Board of Directors of ADDvise Group has adopted financial targets for the financial year 2023:

• Net sales pro forma rolling 12 months shall by the end of the year reach SEK 1.6 billion.
• EBITDA pro forma rolling 12 months shall by the end of the year reach SEK 330 million.

The below current long-term financial targets for ADDvise Group remain unchanged.

• Revenue growth: Annual growth in revenue of at least 25%. Growth is both acquired and organic.
• Profitability: EBITDA-margin of 20%.
• Capital structure: Net interest-bearing debt in relation to EBITDA shall not exceed 3.0 times.
• Dividend: 25 % of previous year EBT, excluding revaluation of earn-outs, shall be paid as dividend to the shareholders.

The financial targets of ADDvise Group should not be seen as a forecast. The targets are goals which the Board of Directors considers reasonable given the present market conditions.

For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisegroup.se

Important information:

This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on February 23, 2023, at 07:30 CET.

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare.

Sid 1/2

---

ADDvise

Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group's shares are listed on Nasdaq First North Premier and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.

Sid 2/2